A clinical calculator to personalize chemotherapy in early-stage high risk epithelial ovarian cancer

Objectives: To determine the utility of a clinical calculator to predict the benefits of chemotherapy and outcomes in women with early stage high risk ovarian cancer. Methods: Data from 2006-2015 was abstracted from the National Cancer Database. All patients had stage I, grade 3; stage IC, stage II, or clear cell carcinoma. Using a Cox regression model, based on demographic, surgico-pathologic, and laboratory characteristics, a clinical score was developed. Propensity score matching was used to reduce bias between patients who did and did not receive chemotherapy. The clinical calculator was validated by both bootstrapping and in an independent validation set. Results: Of 8,289 patients with early stage high risk ovarian cancer, 6,990 (84%) did and 1,299 (16%) did not receive chemotherapy. Patients who underwent chemotherapy had a 5-year overall survival (OS) of 85% vs 80% in those without treatment (p Download : Download high-res image (40KB) Download : Download full-size image Conclusions: Our results suggest a clinical calculator can help direct chemotherapy decision making for women with high risk early stage ovarian cancer.